Acute cardiac care & resuscitationRandomised controlled trial
Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery
- Randomised controlled trial
- multicentre
- double-blind
- placebo-controlled
- 2 academic medical centres and 5 nonacademic hospitals in the Netherlands
Authors' conclusion
In patients undergoing elective cardiac surgery, 4 doses of dapagliflozin, beginning the day before surgery, reduced the incidence of AKI during the 7-day postoperative period.
Study context
- Population
- Adults undergoing elective cardiac surgery778 (99%) completed follow-up
- Participants
- 784 adults
- Comparison
- Dapagliflozin vs placebo before and after cardiac surgery
- Dapagliflozinn = 392
- Placebon = 392reference
- Primary endpoint
- Acute kidney injury (AKI) by KDIGO criteria (creatinine rise ≥0.3 mg/dL within 48 h, 1.5-fold within 7 days, or urine output <0.5 mL/kg/h for 6–12 h)
- Follow-up
- First 7 postoperative days
Primary result
AKI · 7 days after surgery
Relative risk
0.54
95% CI 0.45–0.65
P < 0.001
By group
Dapagliflozin vs Placebo
RR 0.54 (95% CI 0.45–0.65); P < 0.001
As reported in the abstract
Safety
AF · most frequent adverse event
Reoperation · most frequent adverse event
Original publication
Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery. JAMA. Published 1 September 2026. doi:10.1001/jama.2026.9268
Summarised from the published abstract; every number is checked against it